Tudor Investment Corp ET AL Purchases 51,217 Shares of BioLife Solutions, Inc. $BLFS

Tudor Investment Corp ET AL raised its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 85.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,356 shares of the medical equipment provider’s stock after buying an additional 51,217 shares during the quarter. Tudor Investment Corp ET AL’s holdings in BioLife Solutions were worth $2,841,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Qube Research & Technologies Ltd lifted its holdings in shares of BioLife Solutions by 2,399.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock worth $5,352,000 after acquiring an additional 238,533 shares during the period. Summit Creek Advisors LLC bought a new position in BioLife Solutions in the third quarter valued at approximately $4,905,000. Ameriprise Financial Inc. increased its stake in BioLife Solutions by 11.3% in the second quarter. Ameriprise Financial Inc. now owns 1,080,371 shares of the medical equipment provider’s stock valued at $23,271,000 after acquiring an additional 109,959 shares during the last quarter. Deerfield Management Company L.P. raised its position in BioLife Solutions by 713.4% during the third quarter. Deerfield Management Company L.P. now owns 111,195 shares of the medical equipment provider’s stock valued at $2,837,000 after purchasing an additional 97,525 shares in the last quarter. Finally, Bank of America Corp DE raised its position in BioLife Solutions by 16.9% during the second quarter. Bank of America Corp DE now owns 671,731 shares of the medical equipment provider’s stock valued at $14,469,000 after purchasing an additional 97,354 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other BioLife Solutions news, CFO Troy Wichterman sold 990 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the completion of the transaction, the chief financial officer owned 150,746 shares of the company’s stock, valued at $3,857,590.14. This represents a 0.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen A. Foster sold 96,923 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the completion of the transaction, the insider owned 113,742 shares of the company’s stock, valued at $2,291,901.30. This represents a 46.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 101,956 shares of company stock valued at $2,068,241 over the last quarter. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $18.59 on Friday. The company’s 50 day moving average price is $21.71 and its two-hundred day moving average price is $24.41. The firm has a market capitalization of $897.90 million, a P/E ratio of -168.98 and a beta of 1.90. BioLife Solutions, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $29.62.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a report on Monday, December 29th. Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Finally, Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.